Progress in the treatment of psoriasis is undeniable. However, not everything Griffiths and colleagues discuss has come to ...

Johnson & Johnson has reported positive outcomes from its Phase III trial of oral icotrokinra for treating plaque psoriasis.

"SEC outperformed placebo by effectively reducing pruritus intensity, restoring clinical normalcy to skin lesions, and ...

Biosimilars show comparable safety with Humira among new users with psoriasis in a multinational cohort study, but ...

The drug, called icotrokinra and developed together with Protagonist Therapeutics, is an oral peptide designed to tamp down ...

Results for icotrokinra (JNJ-2113) have shown the drug’s potential to offer significant relief for patients suffering from moderate-to-severe plaque psorias ...

Top-line results show that 64.7% of patients achieved clear or almost clear skin measured using the Investigator's Global ...

Discover how immune checkpoint inhibitors, a revolutionary cancer therapy, increase psoriasis risk. Essential insights for ...

Psoriasis severity and systemic inflammation linked to cardiovascular disease: insights for better patient care.

Low patient satisfaction in psoriasis and psoriatic arthritis for clinicians and treatment is tied to need for better ...

The study, published in JAMA Dermatology, revealed that psoriasis severity, measured by the Psoriasis Area and Severity Index ...